258 related articles for article (PubMed ID: 32054838)
1. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.
Nelson L; Tighe A; Golder A; Littler S; Bakker B; Moralli D; Murtuza Baker S; Donaldson IJ; Spierings DCJ; Wardenaar R; Neale B; Burghel GJ; Winter-Roach B; Edmondson R; Clamp AR; Jayson GC; Desai S; Green CM; Hayes A; Foijer F; Morgan RD; Taylor SS
Nat Commun; 2020 Feb; 11(1):822. PubMed ID: 32054838
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
3. Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.
Nelson L; Barnes BM; Tighe A; Littler S; Coulson-Gilmer C; Golder A; Desai S; Morgan RD; McGrail JC; Taylor SS
Chromosome Res; 2023 Aug; 31(3):21. PubMed ID: 37592171
[TBL] [Abstract][Full Text] [Related]
4. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
[TBL] [Abstract][Full Text] [Related]
5. The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.
Penner-Goeke S; Lichtensztejn Z; Neufeld M; Ali JL; Altman AD; Nachtigal MW; McManus KJ
PLoS Genet; 2017 Apr; 13(4):e1006707. PubMed ID: 28376088
[TBL] [Abstract][Full Text] [Related]
6. Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer.
Li LY; Kim HJ; Park SA; Lee SH; Kim LK; Lee JY; Kim S; Kim YT; Kim SW; Nam EJ
Cancer Res Treat; 2019 Jul; 51(3):1117-1127. PubMed ID: 30428638
[TBL] [Abstract][Full Text] [Related]
7. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
[TBL] [Abstract][Full Text] [Related]
8. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.
Zhang M; Zhuang G; Sun X; Shen Y; Wang W; Li Q; Di W
Diagn Pathol; 2017 Feb; 12(1):16. PubMed ID: 28148293
[TBL] [Abstract][Full Text] [Related]
10. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
[TBL] [Abstract][Full Text] [Related]
11. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
[TBL] [Abstract][Full Text] [Related]
12. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
[TBL] [Abstract][Full Text] [Related]
13. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
14. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
15. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
16. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
17. Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids.
Bolhaqueiro ACF; Ponsioen B; Bakker B; Klaasen SJ; Kucukkose E; van Jaarsveld RH; Vivié J; Verlaan-Klink I; Hami N; Spierings DCJ; Sasaki N; Dutta D; Boj SF; Vries RGJ; Lansdorp PM; van de Wetering M; van Oudenaarden A; Clevers H; Kranenburg O; Foijer F; Snippert HJG; Kops GJPL
Nat Genet; 2019 May; 51(5):824-834. PubMed ID: 31036964
[TBL] [Abstract][Full Text] [Related]
18. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
[TBL] [Abstract][Full Text] [Related]
19. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.
Bronder D; Tighe A; Wangsa D; Zong D; Meyer TJ; Wardenaar R; Minshall P; Hirsch D; Heselmeyer-Haddad K; Nelson L; Spierings D; McGrail JC; Cam M; Nussenzweig A; Foijer F; Ried T; Taylor SS
Dis Model Mech; 2021 Nov; 14(11):. PubMed ID: 34569598
[TBL] [Abstract][Full Text] [Related]
20. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
